“Final preparation for the start of commercialization of an innovative test to assess the risk of Alzheimer’s disease – ALTEST”

The project was co-financed by the European Union from the European Regional Development Fund.

Project applied to: “Innovations of newly established SMEs-Phase II”

Project label: KK.03.2.2.04.006

Project description:

Majority of brain diseases are discovered too late for successful treatment!

Dementia, the most common serious medical problem of the modern society is discovered when an individual or family members notice significant changes in a person’s behavior and abilities. When discovered at that stage – when the symptoms became obvious – more than 50% neurons are already significantly impaired, which makes treatment unsuccessful!

How Alzheimer’s can affect you and the people you love…

Alzheimer’s is the most common cause of dementia, a disease marked by memory loss and progressive deterioration of everyday functions. It’s not only about memory – people suffering from Alzheimer’s disease progressively lose the ability to plan everyday duties; to dress themselves, to perform basic functions, like turning on /off lights, TV, locking the door, etc.

Alzheimer’s disease – affected individuals depend completely on family and medical care 24/7

Alzheimer’s disease accounts for 60 to 80 % of dementia cases and although more often in persons above 65, it can appear in any phase of life. Alzheimer’s disease can affect you, too!

The only chance to slow down, stop or even revert the symptoms of dementia is to discover it on time!

Check My Brain is the only test currently available on the market which can recognize signs of developing brain disease on time!

“Development of devices for the application of electromagnetic fields in the therapy and monitoring of patients with brain diseases (EMHANCE)”

The project is co-financed from the Budget of the Republic of Croatia, through the Ministry of Economy, Entrepreneurship and Crafts and implemented by the Croatian Agency for Small Business, Innovation and Investment (HAMAG-BICRO).

Project applied to: “Innovative Concept Verification Program (PoC8)”

Project label: PoC8_1_4

Project description:

With the cost of medical care for patients with brain diseases, which reached € 800 billion a year in the European Union alone, they represent a huge financial burden for society. Shortening the rehabilitation time by just 10% would save € 50 billion a year. The EMHANCE project builds upon our experience in treating brain ischemia with physics of electromagnetism. The goal is to design an innovative device for the treatment and monitoring of patients with neurodegenerative, neuroimmune, demyelinating and neurovascular diseases using electromagnetic fields. We expect electromagnetic fields to increase the rate of tissue regeneration, while the negative elements of hypoxia and inflammation will be mitigated. At the same time, our device will have a built-in electromagnetic field sensor to monitor the patient’s condition while receiving therapy by detecting the strength of the allowed electromagnetic fields around the neurons. This built-in sensor will evaluate changes in the brain’s electromagnetic fields in real time in response to therapy and will send feedback to the electromagnetic field emitter. Although, in recent years, publications in the best journals, including ours, have shown that electromagnetic fields can have a positive effect on brain tissue, there is no such or similar device on the market. Therefore, the potential for commercialization is huge. Furthermore, throughout the project, we will work on market research and patent applications that will include a variety of applications of the designed system from positive effects on neurodegeneration to reducing pain and generally improving patient health.

Our preliminary results demonstrate a statistically significant difference in activity of glial cells, neuronal stem cells and neurons between treatment and control groups. These suggest that our device has the potential to initiate microglial and astrocytic activation, leading to formation of an astrocytic scar and, therefore, neuroregeneration as well as increased neuronal activity, leading to strengthening of existing connections and potential formation of new connections. On the other hand, this device could also be used in inhibiting glial cell or neuronal activity in cases where those are increased and lead to development of new pathologies.